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Abstract
Background: Targeted therapy with BRAF and MEK inhibitors has improved the survival of patients with BRAF-
mutated metastatic melanoma, but most patients relapse upon the onset of drug resistance induced by mechanisms
including genetic and epigenetic events. Among the epigenetic alterations, microRNA perturbation is associated with
the development of kinase inhibitor resistance. Here, we identified and studied the role of miR-146a-5p dysregulation
in melanoma drug resistance.
Methods: The miR-146a-5p-regulated NFkB signaling network was identified in drug-resistant cell lines and melanoma
tumor samples by expression profiling and knock-in and knock-out studies. A bioinformatic data analysis identified
COX2 as a central gene regulated by miR-146a-5p and NFkB. The effects of miR-146a-5p/COX2 manipulation were
studied in vitro in cell lines and with 3D cultures of treatment-resistant tumor explants from patients progressing
during therapy.
Results: miR-146a-5p expression was inversely correlated with drug sensitivity and COX2 expression and was reduced
in BRAF and MEK inhibitor-resistant melanoma cells and tissues. Forced miR-146a-5p expression reduced COX2 activity
and significantly increased drug sensitivity by hampering prosurvival NFkB signaling, leading to reduced proliferation
and enhanced apoptosis. Similar effects were obtained by inhibiting COX2 by celecoxib, a clinically approved COX2
inhibitor.
Conclusions: Deregulation of the miR-146a-5p/COX2 axis occurs in the development of melanoma resistance to
targeted drugs in melanoma patients. This finding reveals novel targets for more effective combination treatment.
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Introduction
Treatment with BRAF and MEK inhibitors (BRAF/
MEKi) has significantly improved the outcome of meta-
static cutaneous melanoma patients with BRAF-mutated
tumors. However, in the majority of patients, the clinical
benefits are limited by the emergence of drug resistance
[1]. Although BRAF/MEKi-resistant patients can benefit
from different therapeutic opportunities, such as im-
mune checkpoint blockade, strategies aimed at impairing
the onset of resistance by drug combinations remain an
urgent unmet clinical need.
The complex network of genomic modifications driving
tumor evolution under pressure from drug treatment
leads to MAPK signaling reactivation and/or AKT path-
way sustainment and strongly conditions the tumor
microenvironment (TME) [2]. Despite treatment, epigen-
etic changes governing drug-induced melanoma cell plas-
ticity and disease progression activate protumorigenic
signaling pathways that include microRNAs (miR) as reg-
ulators [3]. miR act in a cell context-dependent manner by
playing key regulatory roles in cell survival and prolifera-
tion signaling pathways, contributing to the acquisition of
BRAF/MEKi resistance [4, 5]. Our previous work
highlighted the link between the acquisition of an HIF1/
NFkB-directed proinflammatory phenotype and the dys-
regulation of a set of miR involved in prosurvival signaling
pathways in BRAFi-resistant melanoma cell lines [6]. The
acquisition of an HIF1/NFkB-directed proinflammatory
phenotype was characterized by the induced production
and release of several factors, including TNFα, CCL5, IL6,
VEGFA, CXCL8, PGE2 and CCL2, which had a prosurvi-
val effect on melanoma cells [6].
miR-146a-5p (miR-146a) is transcriptionally regulated
by NFkB. It negatively controls NFkB-associated signaling
pathways and release of proinflammatory cytokines
through downregulating IRAK1 and TRAF6, and by nega-
tively regulating expression of TNFα [7–11]. In melan-
oma, antithetic roles for miR-146a as both a tumor
suppressor and tumor promotor were described [12–15],
and its genetic polymorphism was associated with melan-
oma risk [16]. In particular, miR-146a overexpression was
reported to promote melanoma cell growth by downregu-
lating its direct targets NUMB and LFNG, which are in-
volved in the NOTCH/PTEN/AKT pathway [12, 13].
Other investigators reported miR-146a involvement in the
regulation of melanoma cell migration and invasive ability
via targeting SMAD4 [15], ITGAV and ROCK1 [13].
Nonetheless, in other tumor types, such as breast, pancre-
atic and gastric cancer, miR-146a was reported to suppress
cell proliferation, invasion and metastasis by repressing
EGFR expression [7]. In lung cancer, miR-146a overex-
pression was shown to restore cisplatin sensitivity by tar-
geting cyclin J and ATG12, while in liver cancer, miR-
146a expression increased the radiosensitivity of tumor
cells by downregulating RPA3 expression [7]. Of note, by
negatively regulating EGFR expression, miR-146a could
enhance the antitumor effects of drugs targeting this re-
ceptor [7].
Among the proinflammatory factors involved in tumor
progression, cyclooxygenase-2 (COX2) and its product
prostaglandin E2 (PGE2) have been found to be upregu-
lated in many cancer types, favoring cell growth and sur-
vival and contributing to the generation of an immune
suppressive TME [17]. Prostaglandin production de-
pends on the activity of two isoforms of the COX en-
zyme, COX1 and COX2. While COX1 is constitutively
expressed, COX2 is induced by different factors, such as
growth factors and proinflammatory cytokines, including
CCL2. Celecoxib is a nonsteroidal anti-inflammatory
drug that specifically inhibits COX2, commonly used for
the treatment of rheumatoid arthritis [18]. This drug is
currently being repurposed in a clinical trial evaluating
its treatment and prevention of cancer [18].
Notably, low miR-146a levels have been found in many
tumor types, including melanoma [7], and were associ-
ated with increased COX2 levels in lung cancer [19].
However, the implication of the miR-146a/COX2 axis
and its potential inhibition by celecoxib has not yet been
investigated in the context of BRAF/MEKi resistance.
Here, we identified the miR-146a/COX2 axis as playing
a critical role in the mechanisms sustaining melanoma
resistance; thus, this axis represents a druggable signal-
ing pathway for improving the effects of BRAF/MEKi
therapy in melanoma patients.
Methods
Cell cultures and reagents
The melanoma cell lines used in this study were described
previously [6] and were periodically checked for myco-
plasma and authentication by STR analysis (Gene Print 10
System, Promega, Fitchburg, WI, USA). Cell Counting kit
8 (CCK8, Sigma) was used to determine cell proliferation,
LDH cytotoxicity assay kit (Pierce, Waltham, MA, USA)
for LDH release, and Caspase-Glo 8 and 3/7 assays for de-
tecting activated caspases (Promega, Fitchburg, WI, USA).
The Prostaglandin E2 ELISA Kit (Cayman Chemical, Ann
Arbor, MI, USA) was used for the measurement of PGE2
from culture supernatant of melanoma cells and of 3D
cultures. Vemurafenib (PLX4032), Dabrafenib (BRAFi)
and Trametinib (MEKi) were purchased (Selleck, Hous-
ton, TX, USA) and used at 3 μM for PLX4032 and 3 nM
for BRAF/MEKi; recombinant sTRAIL (Vinci Biochem,
Florence, Italy) was used at 50 ng/mL and the COX2 in-
hibitors celecoxib and NS398 (Sigma) at 50 μM.
For cells transfection of miR mimic, inhibitor and con-
trol oligos (50 nM), PTGS2 siRNA or siRNA control
(100 nM) (Thermo Fisher Scientific, Waltham, MA,
USA), Metafectene was used (Biontex, Munich,
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Germany). Transfection efficiency was monitored by
qRT-PCR for miR-146a and by western blot for COX2
protein expression at 72 h. For Luciferase Assay,
pLightSwitch-3’UTR-PTGS2 or the pLightSwitch empty
vector (1 μg) (Active Motif, Carlsbad, CA, USA) were
cotrasfected with either miR-146a mimic or negative
control for 48 h and the LightSwitch Luciferase assay
system (Active Motif) was used to analyze the lumines-
cence production. All experiments were performed at
72 h after treatment, seeding 1,5 × 104 cells/well in 96
wells plates.
Western blot analysis and antibody array
Total protein was extracted from transfected cells using
RIPA buffer (Thermo Fisher Scientific) and quantified
using BCA protein assay (Bio-Rad, Hercules, CA, USA).
Cell lysates (30 μg) were resolved on 4–12% SDS-PAGE
and transferred to nitrocellulose membranes (Thermo
Fisher Scientific); membranes were incubated with specific
antibodies (supplementary Table S1). Peroxidase-
conjugated secondary antibodies anti-mouse immuno-
globulin and anti-rabbit immunoglobulin G were used.
Antibody Array kit for Human Apoptosis Signaling (Ray-
biotech, Peachtree Corners, GA, USA) was used to test
protein lysates. Chemiluminescence was measured by
Uvitec Imaging System (Cleaver Scientific, Cambridge, UK)
and quantified by Nine-Alliance software.
RNA extraction and qRT-PCR analysis
RNA was extracted from melanoma cells and specimens
with the NucleoSpin RNA isolation kit (Macherey Nagel,
Bethlehem, PA, USA). Extracted RNAs were quantified
spectrophotometrically, and the absorbance ratio at 260/
280 and 260/230 were measured to assure RNA quality
and purity. qRT-PCR analysis was performed using
Thermo Fisher Scientific reagents for gene transcripts
and Exiqon reagents for miR (supplementary Table S1).
The endogenous controls used for normalization were
ACTB and RPL13A for genes and U6 snRNA for miR.
qRT-PCR was carried out in triplicate and run on the
ABI Prism 7900HT or on the QuantStudio 7 Flex instru-
ments and analysis was performed using SDS software,
version 2.2.2 and with QuantStudio 6 and 7 Flex soft-
ware. The results are presented as 2−ΔCt ± SD for direct
comparisons.
miR and gene expression profiling data analysis
miR expression profiles were generated using Nano-
String nCounter Human v2 miR Expression Assay that
contains 800 human endogenous miR. Raw data were
normalized and log2-transformed using the NanoString-
Norm R package [20], setting the required parameters to
the following values: Probe.Correction.Factor to “adjust”;
CodeCount to “sum”; Background to “mean”;
SampleContent to “top.geo.mean” and OtherNorm to
“none”. Raw and processed miR expression data are
available at the NCBI Gene Expression Omnibus with
accession date GSE141314. Raw miR expression data for
GSE67635 [21] and GSE68841 [6] were downloaded
from GEO and pre-processed using limma [22] with
“normexp” method for background correction, quantile
normalization and log2 transformation. Replicated
probes were collapsed calculating the average expression
and for each miR the probe with highest variance across
samples was selected. Differential expression analysis
was carried out using limma [22] (paired design for
NanoString data). P-values were corrected for multiple
testing using the Benjamini-Hochberg false discovery
rate (FDR) method. A nominal p-value < 0.05 was ap-
plied to select differentially expressed miR for Nano-
String data and an FDR < 0.05 for GSE67635 and
GSE68841.
Gene expression profiles of metastatic tumor samples
were generated using HumanHT-12 WG-DASL V4.0 R2
expression beadchip (Illumina, San Diego, CA, USA).
RNA labeling, processing and hybridization were per-
formed according the manufacturer’s standard protocols.
Microarrays were scanned with Illumina BeadArray
Reader and raw expression data were obtained using
Illumina BeadStudio v3.3.8 and processed using the lumi
Bioconductor package [23] as previously described [6].
The data were deposited in GEO with accession number
GSE141484. Functional analyses were generated through
the use of Ingenuity pathway Analysis (IPA) (Qiagen,
Hilden, Germany).
3D cultures of tumor explants in RCCS bioreactor
3D Cultures of Melanoma Tissue explants were set in
Rotary Cell Culture System Bioreactor (RCCS) (Synthe-
con Inc., Houston TX, USA) as described by Ferrarini
[24]. Tumor tissue cubes were obtained by a 3 mm bi-
opsy puncher from tumor specimens obtained from the
pathologist, and cultured in duplicate in the bioreactor
chambers for 3 days, in culture medium or in the pres-
ence of BRAF/MEKi (3 nM) and/or miR-146a mimic or
negative control synthethic oligos (50 nM). When recov-
ered, samples were halved, a part was fixed in formalin
and paraffin-embedded for histopathology, and a part
was fixed in RNAlater solution (Thermo Fisher Scien-
tific) for RNA analysis. Quantification of secreted cyto-
kines in the 3D culture supernatant was carried by
Cytometric Bead Array (CBA, BD Biosciences, San Jose,
CA, USA) using the BD software FCAP Array v3.0.1.
Immunohistochemistry
Melanoma sections were stained by specific antibodies
(supplementary Table S1) for ki67, cleaved Caspase 3,
phospho-ERK, and COX2 after antigen retrieval
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performed by heating in a pressure cooker with 0,5 mM
EDTA pH 8 for 15 or 20min and using a peroxidase-
labelled polymer (UltraVision Quanto Detection System
HRP Polymer, Thermo Fisher Scientific) and brown
DAB as a chromogen (Dako Agilent, Glostrup,
Denmark). Sections were scanned using the Aperio
ScanScope XT systems (Aperio Technologies, Leica
Microsystems).
Statistical analysis
Statistical analyses were performed using Prism software
v.5 and v.8 (La Jolla, CA, USA). Comparisons between
continuous variables in two groups were performed
using an unpaired two tailed Student’s t-test or Mann-
Whitney U test. For comparisons involving more than
two groups, one-way ANOVA was used, followed by
Bonferroni correction. For comparisons between two
dose-response curves, two-way ANOVA followed by
Bonferroni correction was used. The correlation between
linear variables was calculated using Pearson or Spear-
man’s correlation coefficients. Drug interaction was eval-
uated by a standard approach that allows a value to be
assigned to a drug combination (interaction index); the
interaction index was calculated as the ratio between ex-
pected cell growth and observed cell growth. If the ex-
perimentally measured effect of the drug combination
was equal to, higher than or lower than 1, the combin-
ation was considered to be additive, synergistic or antag-
onistic, respectively. Data are presented as the mean ±
SD.
Results
miR-146a is regulated in BRAFi-resistant melanoma cell
lines
To expand the analysis of the miR involved in establish-
ing a resistant phenotype, we analyzed the miR expres-
sion profiles of six melanoma cell lines which developed
acquired resistance to vemurafenib (PLX4032) and cross
resistance to dabrafenib (BRAFi), trametinib (MEKi) and
the combination of dabrafenib and trametinib (BRAF/
MEKi) and their parental drug-sensitive counterparts
(supplementary Fig. S1A). We identified 22 differentially
expressed miR between the resistant and sensitive cells;
of these miR, 6 were upregulated, and 16 were downreg-
ulated in the resistant cells (supplementary Table S2).
To strengthen our findings and focus on miR which
could be relevant for resistance, acquired and intrinsic,
we intersected these 22 miR to those previously identi-
fied in our laboratory in a similar profiling setting
(GSE68841; 6) and to those differentially expressed be-
tween melanoma cell lines sensitive (cluster 1) or intrin-
sically resistant to the BRAFi PLX4720 (cluster 2)
(GSE67635, 21). Three miR were commonly modulated
in all three datasets (Fig. 1a). Two of them, miR-100-5p
and miR-125b-5p, upregulated in resistant cells, have
been previously investigated [6]. The third miR, miR-
146a, was downregulated in resistant cells and its down-
regulation was indeed confirmed in each of the six
BRAFi-resistant melanoma cell lines of the current study
compared to their sensitive counterparts (Fig. 1b). First
evidence of its association with drug resistance was given
by the inverse correlation of miR-146a and the IC50
values of BRAF/MEKi used in combination or as single
agents (Fig. 1c and supplementary Fig. S1B).
Modulation of miR-146a affects the BRAF/MEKi drug
response in melanoma cells
To assess whether miR-146a expression levels affect the
drug sensitivity of melanoma cells, we transiently manip-
ulated its expression in gain- and loss-of-function assays
and tested the effects on kinase inhibitor treatment.
miR-146a hyperexpression in cell lines with acquired or
intrinsic resistance significantly reduced cell growth, in-
creased cytotoxicity and apoptosis induced by drug
treatment compared with control conditions (Fig. 1d
and supplementary Fig. S1CE). Conversely, following
miR-146a inhibitor transfection, the effect of drug treat-
ment on cell cytotoxicity and apoptosis was reduced in
sensitive LM16 cells (supplementary Fig. S1D).
Interestingly, we observed that resistance to BRAF/
MEKi was extended to apoptosis determined by expos-
ure to recombinant soluble TRAIL (sTRAIL), a func-
tional mediator of cytotoxic immune cells
(supplementary Fig. S1A). miR-146a overexpression in
drug-resistant cells increased their sensitivity to sTRAIL-
induced apoptosis (Fig. 1e, supplementary Fig. S1E),
while miR-146a inhibition was protective (supplemen-
tary Fig. S1D). miR-146a expression levels were nega-
tively correlated with sTRAIL-induced caspase 3/7 levels
(Fig. 1f), further supporting the functional contribution
of miR-146a to regulating cell apoptosis.
Forced expression of miR-146a reduces drug resistance
via AKT/ERK and NFkB signaling cascade
BRAFi resistance is associated with a proinflammatory
phenotype, characterized by the endogenous upregula-
tion of the HIF1/NFkB-directed gene expression of cyto-
chemokines, growth factors and other inflammatory me-
diators [6]. Because miR-146a is subject to NFkB regula-
tion [8], we tested its involvement in drug resistance-
induced NFkB modulation. miR-146a ectopic expression
decreased NFkB activity (Fig. 2a), acting as a negative
feedback loop regulator [9]. As expected, the prosurvival
AKT/mTOR/ERK pathway and MAPK signaling path-
way were downregulated, as indicated by the reduced
pAKT, AKT, pp70S6K and pERK levels (Fig. 2a). The
link between miR-146a downregulation and melanoma
cell growth is sustained by the results of IPA analysis
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showing that putative miR-146a target genes, upregu-
lated in GSE68841 [6], associate to “Cellular Growth and
Proliferation” and to “Cellular Movement” Network
functions.
To identify genes regulated by miR-146a via direct tar-
geting or NFkB, we first extracted those differentially
expressed in the GSE68841 dataset [6] from the list of
1667 NFkB-transcribed genes reported in the database
built by Yang [25]. Twenty-four out of 527 common
genes were validated direct target genes of miR-146a ac-
cording to the miRWalk 2.0 database (supplementary
Table S3) [26]. They included CCL5, CXCL8, EGFR and
Fig. 1 Downregulation of miR-146a is associated with resistance to BRAF/MEKi in melanoma cell lines and its manipulation affects drug response
and TRAIL-induced apoptosis. a Venn diagram illustrating common miR associated with BRAF/MEKi resistance in GSE141314, GSE67635 and
GSE68841 datasets. b miR-146a shows significant downregulation in melanoma resistant cells (R) compared with their sensitive counterparts (S).
logFC: log2 Fold Change. P-value obtained from differential expression analysis performed with limma package. c Inverse correlation between
miR-146a expression levels and IC50 values of combined BRAF/MEKi in melanoma cell lines (Spearman analysis). d Forced expression of miR-146a
(+m-miR-146a) increases the effects of BRAF/MEKi treatment in LM16R, LM69 and LM70 cell lines, as shown by reduced cell growth and increased
cell cytotoxicity and apoptosis, evaluated by CCK8, LDH and caspase 8 and 3/7 activity. LM69 and LM70 short term melanoma cultures were
generated from treatment resistant melanoma lesions surgically excised from two patients. Based on qRT-PCR results, upon transfection miR-146a
levels were up to 70-fold higher (range 76–1223) than the levels detectable in cells transfected with control oligos. Data are plotted as fold
increase compared to cells transfected with mimic negative control. *: p < 0.05, **: p < 0.01, ***: p < 0.0001 by Student’s unpaired t test. e Forced
expression of miR-146a increased the effect of treatment with sTRAIL. f Positive correlation between the levels of miR-146a expression and of
activated caspase 3/7 induced by sTRAIL treatment (Spearman analysis). RLU: Relative Light Unit. Results shown are representative of 2
experiments performed in triplicate (d, e)
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PTGS2 genes related to the proinflammatory and inva-
sive signatures of resistant cells [6, 27]. In addition,
among the genes indirectly regulated by miR-146a
through NFkB activity, we found CCL2, IL6, and
VEGFA, which contribute to the proinflammatory
phenotype, CD274 (PDL1), which promotes melanoma
Fig. 2 miR-146a regulates NFkB-related signaling pathways associated with resistance and directly targets PTGS2. a Immunoblot showing reduced
levels of NFkB, AKT, p70S6K, and ERK in melanoma cells transfected with synthetic miR-146a (m-miR-146a) compared to mimic negative control
transfectants (left). Reduction of phosphorylated proteins in miR-146a transfectants calculated by signal quantification (right). b Reduced expression of
miR-146a target genes in transfectants (m-miR-146a: miR-146a mimic; S: mimic scrambled control). c Expression levels of PTGS2 and PTGES genes in
resistant cell lines (R) compared to their sensitive counterparts (S). d Positive correlation between PTGS2 expression and IC50 values of BRAF/MEKi in
melanoma cell lines (Spearman analysis). e Higher levels of COX2 protein expression in resistant cells (R) compared to their sensitive counterparts (S).
Specific signals were quantified and expressed as the ratio of COX2/actin intensity. f Reduction of COX2 protein expression in LM16R resistant cells
transfected with miR-146a mimic (m-miR-146a) and increased levels in LM36 parental sensitive cells transfected with miR-146a inhibitor (i-miR-146a).
Changes in COX2 expression were calculated by signal quantification. P values were calculated by Student’s unpaired t test in A and F, and by Mann-
Whitney U test in B. *: p < 0.05, **: p < 0.01, ***: p < 0.0001
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cell proliferation [28], and BCL2L1 and MCL1 antiapop-
totic genes. All these genes displayed reduced expression
upon forced miR-146a expression in melanoma cells
(Fig. 2b).
miR-146a impairs drug resistance by regulating the
expression of PTGS2 gene encoding COX2.
Among the predicted miR-146a gene targets, the
PTGS2 gene encoding COX2 attracted our attention be-
cause COX2 overexpression was reported to be associ-
ated with tumor progression and poor prognosis in
melanoma [29–31]. COX2 transcript and protein expres-
sion levels were higher in several cells with acquired re-
sistance compared to their sensitive counterparts and
positively correlated with BRAF/MEKi resistance, reveal-
ing a direct association between COX2 and resistance
(Fig. 2cde and supplementary Fig. S2B). Resistant cell
lines also showed upregulation of PTGES, the gene en-
coding microsomal prostaglandin E2 synthase 1
(mPGES1), which is functionally coupled with COX2 in
PGE2 production (Fig. 2c).
By luciferase reporter assays, we detected a significant
decrease in luciferase activity upon melanoma cells
transfection with the pLightSwitch-3’UTR-PTGS2 vector
together with the miR-146a mimic when compared with
controls, confirming a role for miR-146a in the post-
transcriptional regulation of PTGS2 (supplementary Fig.
S2A). Finally, forced miR-146a expression in resistant
cells resulted in a decrease in COX2 protein levels, while
inhibition of miR-146a in sensitive cells induced an in-
crease in COX2 levels (Fig. 2f). These findings further
confirm the involvement of miR-146a in COX2
regulation.
Targeting COX2 restores melanoma sensitivity to BRAF/
MEKi
The above results prompted us to investigate whether
targeting COX2 may impact BRAF/MEKi resistance.
COX2 knockdown by small interfering RNA (siCOX2)
reduced COX2 expression levels and enhanced melan-
oma cell sensitivity to BRAF/MEKi (Fig. 3a and supple-
mentary Fig. S2CD). Pharmacologic inhibition of COX2
activity by the selective inhibitor celecoxib and BRAF/
MEKi significantly reduced cell growth and increased
cell cytotoxicity (Fig. 3b and supplementary Fig. S2F).
The combined treatment resulted in an additive inhib-
ition of cell growth (interaction index = 1), a result also
confirmed by dose-response assays (supplementary Fig.
S2FG).
Fig. 3 miR-146a spoils resistance of melanoma cells by repressing COX2 expression. a Silencing of COX2 by siRNA transfection (siCOX2) enhanced cell
growth inhibition and increased cell cytotoxicity and apoptosis upon treatment with BRAF/MEKi. b Combined treatment with celecoxib increased cell
growth inhibition and cytotoxicity by BRAF/MEKi. ●: interaction index = 1. c Increased apoptotic signaling after combination treatment with celecoxib and
BRAF/MEKi. Phosphorylated and cleaved apoptotic factors showing increased expression in cells treated with the drug combination compared to BRAF/
MEKi treated cells (Fold change > 1.3) by apoptosis signaling antibody array analysis. d Reduction of PGE2 release in culture media by treatment with the
COX2 inhibitors celecoxib and NS398, alone or in combination with BRAF/MEKi. All experiments were carried with the LM47R cell line. P values were
calculated by Student’s unpaired t test in B, and by one-way ANOVA followed by Bonferroni correction in D. *: p< 0.05, **: p< 0.01, ***: p< 0.0001
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A screening of apoptosis-related proteins by antibody ar-
rays showed that combined treatment significantly increased
the phosphorylation of the proapoptotic proteins BAD and
caspase 7 through activating SMAD2, JNK and p38/MAPK
apoptosis-related signaling pathways. Moreover, induction of
ATM signaling resulted in non canonical NFkB activation
[32], determining the phosphorylation of components of the
pathways involved in DNA damage-induced apoptosis, such
as PARP1, p53 and TAK1 (Fig. 3c).
One consequence of COX2 overexpression is in-
creased PGE2 production, which has multiple protu-
moral effects, including apoptosis resistance [17].
According to the high expression levels of COX2 and
PTGES, resistant cell lines indeed secreted high levels of
PGE2, which were significantly inhibited upon cell
exposure to the COX2 inhibitors celecoxib and NS398,
independent of BRAF/MEKi treatment (Fig. 3d and
supplementary Fig. S2E). Taken together, these data in-
dicate that the enhanced apoptotic effects induced by
BRAF/MEKi in the presence of COX2 inhibition result
from diminished PGE2 production, which reduces pro-
survival signaling and activates apoptotic pathways and
DNA damage signal transducers.
BRAF/MEKi resistance affects the miR-146a/COX2 axis in
melanoma patients
To determine whether the miR-146a downregulation
and COX2 upregulation observed in BRAF/MEKi-resist-
ant melanoma cell lines in vitro also occurred in vivo in
melanoma patients, we analyzed tumor samples surgi-
cally excised for local treatment from patients undergo-
ing BRAF/MEKi therapy. Tissue immunostaining
confirmed higher COX2 expression in tumor lesions
progressing during BRAF/MEKi therapy compared to
matched pretreatment lesions in 3 out of 7 tested cases
(Fig. 4a and supplementary Table S4). High PTGS2 and
PTGES and low miR-146a expression levels were de-
tected in treatment-resistant tumors when compared to
tumors from untreated patients (Fig. 4b). Despite the
different numbers of treated and untreated samples ana-
lyzed and the diverse levels of gene expression detected
in the tumor samples, significantly higher PTGS2 and
PTGES was evident in tumors from treated patients. For
miR-146a, although several untreated tumors show high
expression levels, while on the contrary low levels are
detected in treated specimens, no significant differences
can be observed between untreated and treated samples.
Fig. 4 Treatment resistant tumors display miR-146a/COX2 axis deregulation. a COX2 immunostaining in tumors excised from patients progressing
during BRAF/MEKi therapy (Post) compared to pre-therapy matched melanoma lesions (Pre). Scale bar: 10 μm. b Lower miR-146a and higher
PTGS2 and PTGES expression levels in tumors progressing in patients during BRAF/MEKi therapy (Treated, n = 12) compared to tumors from
unmatched untreated patients (Untreated, n = 31). *: p < 0.05, **: p < 0.01 by Mann-Whitney U test. c Heatmap showing the gene expression
pattern of PTGS2, CXCL8, PTGES, IL6, VEGFA, CD274, MCL1 in progressing tumors (Post-treatment) compared to matched pre-therapy lesions (Pre-
treatment) from seven metastatic melanoma patients receiving BRAFi therapy
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Similar to what was observed in cell lines, miR-146a
expression levels were inversely correlated with the
levels of its target genes EGFR, CCL2 and BCL2L1 in
melanoma metastases (supplementary Fig. S3). We then
analyzed an in-house gene profiling dataset of seven
matched metastatic tumor samples obtained from a co-
hort of patients before therapy and after the onset of
treatment resistance for expression values of PTGS2 and
of a number of additional direct or indirect miR-146a
targets. In comparison to the matched pre-therapy sam-
ple, resistant lesions from five of the patients (Pts 1, 2, 3,
5 and 6) coordinately displayed higher expression of
PTGS2. The remaining two patients (Pts 4 and 7) had
instead lower expression of PTGS2 in their resistant
sample. Different numbers of additional direct or indir-
ect miR-146a targets, five in Pt 1, four in Pts 5 and 6,
three in Pt 2 and two in Pt 3, displayed an expression
trend similar to PTGS2. Among them, VEGFA, CD274,
MCL1 were upregulated in most of the resistant lesions,
whereas PTGES increase was never observed (Fig. 4c).
Although an heterogenous pattern in term of gene ex-
pression levels was clearly displayed among patients, de-
regulation of the miR-146a/COX2 axis occurs in a
subset of melanoma patients and is associated with the
development of BRAF/MEKi drug resistance.
Functional relevance of miR-146a/COX2 axis manipulation
in BRAF/MEKi resistance
To investigate the effects of miR-146a overexpression and
COX2 inhibition on melanoma tumors, we performed 3D
experiments with tumor explants using a short-term dy-
namic culture system in a bioreactor [24]. The preserva-
tion of TME architecture and cellularity by this culture
system was confirmed in preliminary experiments (supple-
mentary Fig. S4). Compared to control conditions, forced
miR-146a expression led to increased miR-146a levels ac-
companied by decreased PTGS2 transcription and down-
regulation of most of the studied direct and indirect miR-
146a target genes (Fig. 5ac and supplementary Fig. S5A).
In a set of 3D cultures from the lesions of 5
treatment-resistant metastatic patients, forced miR-146a
upregulation led to reduced COX2 protein and gene
levels and decreased PTGES, EGFR, CXCL8, CCL5,
CCL2, IL6 and VEGFA, CD274, MCL1 and BCL2L1
levels (Fig. 5bc). These results indicated that downregu-
lated miR-146a expression occurring through the acqui-
sition of resistance to BRAF/MEKi-activated tumor-
derived components contributes to melanoma survival
and the generation of a tumor-promoting immunosup-
pressive TME; this finding was also confirmed by the re-
duced CCL2, IL6, IL8 and VEGFA secretion in the
culture supernatants (Fig. 5c). Moreover, these observa-
tions led us to test the relevance of COX2 inhibition on
PGE2 production in 3D tumor explants from a BRAF/
MEKi-resistant patient and a treatment naïve patient. In
both tumors, the COX2 inhibitor celecoxib significantly
reduced PGE2 release, demonstrating that COX2 activity
regulates PGE2 production also in tumor tissue (Fig. 5d).
Consistently, a tissue analysis revealed that forced miR-
146a expression remarkably reduced tumor cell prolifer-
ation in 3D cultured explants upon BRAF/MEKi treat-
ment. These effects were observed in 3D cultures of
BRAF-mutated melanoma tumors from naïve patients
(supplementary Fig. S5B) and confirmed in tumors from
patients undergoing treatment (Fig. 5e).
Our results strongly support a central role for the
miR-146a/COX2 axis in modulating key components of
tumor growth and survival associated with the onset of
BRAF/MEKi resistance.
Discussion
In the present study, we depict for the first time a role
of miR-146a in controlling BRAF/MEKi resistance in
melanoma cells, through a mechanism involving COX2.
Chronic exposure to BRAFi induces miR-146a decrease
in melanoma cells and increases expression of COX2,
which boosts tumor cell survival to BRAFi resistance.
Interestingly, we found that the increased BRAF/MEKi
sensitivity induced by forced miR-146a expression in
BRAF/MEKi-resistant cells were achieved by regulating
COX2 expression. Our findings are consistent with pre-
vious observations demonstrating an inverse relationship
between miR-146a and COX2 in lung cancer cells [19].
The analysis of tumors progressing in patients during
BRAF/MEKi treatment revealed that miR-146a downreg-
ulation and the associated COX2 upregulation are not
unique to in vitro models of BRAF/MEKi resistance as
also occur in tumors in vivo. Due to the multiplicity of
molecular alterations that characterize resistant
melanoma, these results point to an important role of
the miR-146a/COX2 axis in resistance. Moreover, the
inhibition of COX2 by forced miR-146a expression in
drug-resistant melanoma lesions is associated with the
downregulation of immunosuppressive cyto-chemokines
contributing to melanoma survival.
Decreased miR-146a expression was previously associ-
ated with drug resistance in lung, cervical, and hepato-
cellular cancer cells, and its overexpression suppressed
cell growth and migration and improved drug sensitivity
by inducing apoptosis [7]. Consistent with these findings,
our study shows that miR-146a is significantly downreg-
ulated in six melanoma cell lines with acquired resist-
ance and poorly expressed in two lines derived from
drug-resistant tumors, and that its overexpression can
restore sensitivity to BRAF/MEKi treatment by affecting
both cell proliferation and apoptosis although with a dif-
ferent effect extent in the studied cell lines. Several stud-
ies have shown that decreased miR-146a expression
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leads to the overexpression of NFkB-mediated inflam-
matory factors contributing to immunosuppression and
disease progression, and that miR-146a replacement can
prevent the inflammatory state [8, 33]. Activation of
NFkB signaling, along with low expression and activity
of MITF, represent hallmarks of melanoma resistance to
targeted therapy, predictive of poor prognosis for pa-
tients treated with BRAF/MEKi. NFkB-high transcrip-
tional state could be present prior to therapy or could be
induced by the acquisition of drug resistance. TNFα is a
Fig. 5 miR-146a overexpression reduces COX2 and increases drug sensitivity in 3D cultures from BRAF/MEKi-resistant tumors. a Overexpression of
miR-146a upon transfection of specific mimic (m-miR-146a) in 3D tumor explants (left) downregulates COX2 expression compared to scrambled-
transfected control (S) (right). b Reduced COX2 immunostaining in 3D cultures upon miR-146a forced expression (m-miR-146a) compared to
mimic scrambled control (S). c Regulation of PTGS2 and miR-146a target genes (upper panel), and decreased release of CCL2, IL6, IL8 and VEGFA
(lower panel) upon treatment with miR-146a mimic (m-miR-146a) and BRAF/MEKi in 3D cultures of resistant tumors in comparison to scrambled-
transfected control (S). AU: arbitrary units. d PGE2 release in culture media from 3D tumor explants upon celecoxib treatment. **: p < 0.01 by
Student’s unpaired t test. e Effects of treatment with BRAF/MEKi combined with transfection of miR-146a mimic (m-miR-146a) or of scrambled
control (S) in resistant tumors: reduction of COX2 and of Ki67 positive cells and increase of cleaved caspase 3 immunostaining. Scale bars: 10 μm
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strong NFkB agonist, able to induce transcriptional
changes promoting drug resistance [34]. In this view, we
speculate that the downregulation of miR-146a could be
considered an epigenetic mechanism contributing to the
maintenance of the NFkB-high transcriptional state as-
sociated to resistance, because of its negative regulation
of NFkB signaling and TNFα expression. In line with
these findings, our experiments demonstrated that miR-
146a ectopic expression in resistant cells modulated the
levels of NFkB activity, downregulated the AKT/mTOR/
ERK and MAPK signaling pathways, and reduced the ex-
pression of NFkB-induced mediators involved in cell
growth and survival, including COX2 and EGFR, the im-
munosuppressive molecules IL8, CCL5, CCL2, IL6,
VEGFA and PDL1, and the antiapoptotic genes BCL2L1
and MCL1.
miR-146a is involved in controlling the inflammatory
response of innate immune system cells, particularly
monocytes/macrophages [35]. Several studies have re-
ported that miR-146a is associated with the negative
regulation of immune activation and cancer-related im-
munosuppression [36]. For instance, miR-146a knock-
out mice with melanoma survived longer [37], and miR-
146a favors immunosuppression by increasing the regu-
latory T cell population in colorectal cancer [38]. In
addition, miR-146a, one of the most studied myeloid
miR [39], has been reported to serve as negative feed-
back modulator in the TLR4-mediated activation of
NFkB–related genes [8] and promote M2 polarization in
both humans and mice [40]. As we also reported, high
miR-146a levels were associated with the induction of
myeloid suppressor cells (MDSCs) and resistance to im-
munotherapy in melanoma patients [41]. Notably, miR-
146a upregulation with concomitant increased COX2,
PDL1, VEGFA, CCL2, IL6, IL8 and MCL1 expression
characterized the MDSCs induced in vitro by melanoma
Fig. 6 Schematic representation of the miR-146a/COX2 axis associated with BRAF/MEKi resistance
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extracellular vesicles from monocytes from healthy do-
nors, suggesting cell type-specific regulation of the miR-
146a/COX2 axis.
COX2 is an inducible enzyme essential in the biosyn-
thesis of PGE2 through the enzyme mPGES1. Overex-
pression of COX2 is reportedly associated with a dismal
prognosis in several tumor types [29, 30, 42]. Constitu-
tive COX2 expression is triggered by pathways activated
by oncogenic stimuli and cyto-chemokines, such as
MAPK, PI3K/AKT and NFkB that are frequently hyper-
expressed in most of resistant tumors [17]. Upregulation
of the COX2/PGE2 axis favors proliferation, angiogen-
esis, invasion, apoptosis resistance, and the activation of
immunosuppressive cells contributing to tumor progres-
sion and therapy resistance [43]. We showed that COX2
and PTGES are both overexpressed in several BRAF/
MEKi-resistant melanoma cells and tumor tissues, and
that COX2 knockdown significantly enhanced drug
effects in melanoma cell. The COX2 selective inhibitor
celecoxib alone and in combination with BRAF/MEKi
has shown tumor inhibitory effects in preclinical melan-
oma studies [44, 45]. Clinical trials have also reported
the effect of COX2 inhibitors, alone or combined with
other treatment modalities, in cancer patients [17, 18].
However, there are no clinical reports investigating the
treatment effect of COX2 inhibitors on BRAF/MEKi
melanoma resistance. Moreover, it has been reported
that COX2 can modulate PDL1 expression, and that
celecoxib reduces PDL1 tumor expression in vitro and
favors cytotoxic T cell responses [46, 47]. Other studies
have described that COX2/mPGES1/PGE2 signaling reg-
ulates PDL1 and IDO in tumor-associated macrophages
and MDSC cells, thus inducing an immunosuppressive
phenotype [48–50]. In line with these reports, our data
showed a coordinated expression of COX2 and PDL1 in
resistant melanoma lesions and in melanoma cells upon
forced miR-146a expression.
Our data show that celecoxib treatment reduced
PGE2 production in resistant cells and in 3D cultures
of resistant tumors, and its combination with BRAF/
MEKi increased the drugs’ effect. Celecoxib-induced
cell death is characterized by the activation of intrin-
sic and extrinsic apoptosis pathways and of NFkB sig-
naling cascades induced by DNA damage, in line with
published literature [18, 32, 51]. Our results support
the targeting of COX2 by direct inhibition with se-
lective drugs or by miR-146a delivery represents an
option to improve the response to targeted therapy in
melanoma patients.
Conclusion
We here report a tumor-suppressive role of miR-146a in
BRAF/MEKi-resistant melanoma and demonstrate that
the manipulation of miR-146a/COX2/PGE2 axis can
restore BRAF/MEKi chemosensitivity (Fig. 6).
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Additional file 2: Supplementary Fig. S1. Altered miR-146a expres-
sion influences BRAF/MEKi sensitivity and apoptosis in melanoma. A) Box-
plots representing IC50 values of 6 matched PLX4032-resistant (R) and
sensitive (S) melanoma cell lines to PLX4032 (vemurafenib), BRAFi (dabra-
fenib), MEKi (trametinib), to the combined treatment BRAF/MEKi, and to
sTRAIL-induced apoptosis. B) Inverse correlation between miR-146a ex-
pression levels and IC50 values of PLX4032, BRAFi and MEKi in melanoma
cell lines (Spearman analysis). C) Forced expression of miR-146a (+m-miR-
146a) in LM16R cell line and in LM69 and LM70 short term cultures in-
creased the effects of PLX4032 treatment as shown by reduced cell
growth and increased cell cytotoxicity and apoptosis, evaluated by CCK8,
LDH and caspase 8 and 3/7 activity. D) Inhibition of miR-146a expression
(i-miR-146a) in LM16 cells increased cell proliferation and decreased the
release of LDH and the apoptosis rate as evaluated by CCK8, LDH and
caspase 3/7 activity. E) Overexpression of miR-146a (m-miR-146a) upon
PLX4032, BRAF/MEKi and sTRAIL treatments in LM47R cells increased cell
cytotoxicity and apoptosis, as evaluated by LDH and caspase 8 and 3/7
activity. Data are plotted compared to scrambled control. *: p < 0.05, **:
p < 0.01, ***: p < 0.0001 by Student’s unpaired t test. Supplementary Fig.
S2. COX2 inhibition increases sensitivity to PLX4032 and to BRAF/MEKi
and reduces PGE2 release. A) Relative luciferase activity after co-
transfection of PTGS2 3’UTR luciferase reporter vector or control vector
with miR-146a mimic or mimic negative control. Experiment was per-
formed in LM16R cells. B) Inverse correlation between miR-146a expres-
sion levels and IC50 values of PLX4032 in melanoma cell lines (Spearman
analysis). C) Western blot analyses showing downregulation of COX2 after
transfection with siRNA against COX2 (siCOX2) compared to scrambled
control (S). COX2 protein levels were downregulated to 15%, as deter-
mined by quantification of the signal and expressed as the ratio of
COX2/Actin intensity. Experiment was performed with LM47R cells. D) Si-
lencing of COX2 by siRNA transfection enhanced cell growth inhibition
and increased cell cytotoxicity and apoptosis upon treatment with
PLX4032 compared to scrambled control. E) PGE2 release in culture su-
pernatants following 24 h treatment with the COX2 inhibitors celecoxib
and NS398, alone or in combination with BRAF/MEKi. F) Combined treat-
ment with celecoxib increased cell growth inhibition and cytotoxicity by
PLX4032. ●: interaction index = 1. G) Dose-dependent effect of celecoxib
alone (5, 10, 20, 40, 50 and 80 μM) and combined with PLX4032 (3 μM)
on cell growth. ●: interaction index = 1 at the dose of 50 μM of celecoxib
combined with PLX4032. P values were calculated by Student’s unpaired
t test in A, D and F, by one-way ANOVA followed by Bonferroni correc-
tion in E, and by two-way ANOVA followed by Bonferroni correction in G.
*: p < 0.05, **: p < 0.01, ***: p < 0.0001. Supplementary Fig. S3. miR-146a
expression levels are inversely correlated with levels of target genes. Ana-
lysis of correlation between miR-146a expression and its target genes
EGFR, CCL2 and BCL2L1 in metastatic melanoma specimens. The rp and
p values resulting from Pearson analysis are shown. Supplementary Fig.
S4. Dynamic culture in bioreactor preserves TME architecture of 3D
tumor explants. Representative histological images of H&E-stained 3D
tumor sections after 3 days culture in bioreactor. The marked areas in the
left panels are shown at higher magnification in the right panels to dis-
play the preserved cellularity and tumor tissue histo-architecture. Scale
bar 80 μM. Supplementary Fig. S5. miR-146a overexpression increases
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drug sensitivity in 3D cultures of tumor explants. A) Modulation of direct
and indirect miR-146a target genes upon transfection of miR-146a mimic
(m-miR-146a) compared to scrambled-transfected control (S) in 3D cul-
tures of BRAF-mutated melanoma tumors from naïve patients. AU: arbi-
trary units. B) Decreased staining for Ki67 and pERK proliferating cells and
increased Caspase 3 positive cells in 3D cultures upon treatment with
BRAF/MEKi and transfection with miR-146a (m-miR-146a) or scrambled
control (S). Scale bar 10 um.
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